Enjoy complimentary customisation on priority with our Enterprise License!
The neurologic disorders therapeutics market size is forecast to increase by USD 27.2 billion at a CAGR of 4.49% between 2023 and 2028. The market is experiencing significant growth due to the approval of novel drugs and the advent of regenerative medicines. CNS Pharmaceuticals' FDA approval of Invega is a prime example of this trend, as is the ongoing development of orphan drugs for rare neurological conditions. R&D efforts are also focused on innovative drug-delivery systems, such as transdermal patches, to improve patient compliance and treatment efficacy. Another trend is the adoption of neurostimulation devices, like Berubicin, which offer alternative treatment options for neurological disorders. Despite these advancements, challenges persist, including the high cost of development and regulatory approval for neurological therapies, as well as the complexities of treating neurological disorders, which require a multidisciplinary approach.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.